Clinical Trials | A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

The University of Virginia is conducting a clinical research study for adults ages 18 years and over with relapsed/ refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received 3 different standard types of medications for CLL/SLL. The purpose of this research study is to find out whether the study drug, NX-5948 (bexobrutideg), is safe and effective in treating R/R CLL or SLL. Bexobrutideg is a study drug designed to target a protein called Bruton Tyrosine Kinase (BTK), which helps cancer cells grow in certain blood cancers like CLL and SLL. If you are eligible to participate in this study, you will receive Bexobrutideg on day 1 of each cycle (every 28 days) to take home with you. You will take a single dose of study drug once a day. The study drug must be taken by mouth with water at least 2 hours before a meal and you should not eat or drink anything but water for at least two hours after taking the study drug. You will receive this study drug as long as you are responding to the treatment. You could be in this study for up to 5 years. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT07221500 [email protected]